ZC2HC1B

Across TCGA pan-cancer cohorts, ZC2HC1B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZC2HC1B data layer compared with 15 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZC2HC1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZC2HC1B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where ZC2HC1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.691	0.189	.003	30	view →
HNSC	DFS	Median	III,IV	0.668	0.896	.011	19	view →
CCRCC	DFS	Median	All	0.608	0.848	.002	10	view →
GBM	OS	Tertile	All	0.508	0.244	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZC2HC1B–LUAD (DFS)

Open the LUAD breakdown →